Nice work Hindmost. Conservative but still compelling buy....

Nice work Hindmost. Conservative but still compelling buy.
another approach is roughly put benitec on same trajectory as similar Co. further down the clinical road. Alny matches that for IP, although their disease targets aren't quite the same big hitters that benitec is going after.
Their pipeline though is bigger, helped by extra cash. Yet they dont have anything commercialised.
$270M to $11B in under 4 years.
that lands benni at around $3B give or take.
But add US investment market factor and its north of that.